ITC Ltd. - Quarterly/Annual Result Disclosures and Notes dated 30 Jun 2025
Auditor and Management Disclosures and Notes for the quarterly results dated 30 Jun 2025
1. ‘Revenue from operations’ includes ‘Gross Revenue from sale of products and services’ and ‘Other operating revenue’.
2. ‘Changes in inventories of finished goods, work-in-progress and stock-in-trade’ should be read as ‘Changes in inventories of finished goods, Stock-in-Trade, work-in-progress and intermediates’.
3. ‘Depreciation, depletion and amortisation expense’ should be read as ‘Depreciation and amortization expense’.
NOTES TO STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2025
1. The unaudited Standalone Financial Results and Segment Results were reviewed by the Audit Committee, and approved by the Board of Directors of the Company at its meeting held on 1st August, 2025.
2. The continuing significant brand building costs covering a range of personal care and branded packaged food products are reflected under 'Other expenses' stated above and in Segment Results under 'FMCG-Others'.
3. 34,22,360 Ordinary Shares of Re. 1/- each were issued and allotted under the Company’s Employee Stock Option Schemes during the quarter ended 30th June, 2025. Consequently, the issued and paid-up Share Capital of the Company stands increased to
Rs. 1251,75,42,141/- as on 30th June, 2025.
4. The Company on 21st May, 2025 acquired 594 Equity Shares of Rs. 10/- each and 2,201 Compulsorily Convertible Preference Shares of Rs. 10/- each of Mother Sparsh Baby Care Private Limited (Mother Sparsh), an associate company, consequent to which the Company’s shareholding in Mother Sparsh aggregated 39.47% of its share capital on a fully diluted basis.
5. The Company on 13th June, 2025 acquired the entire share capital of Sresta Natural Bioproducts Private Limited (SNBPL), consequent to which SNBPL became a wholly owned subsidiary of the Company and its subsidiaries viz., Fyve Elements LLC, USA and Sresta Global FZE, UAE, became step-down wholly owned subsidiaries of the Company with effect from the said date.
6. The Board of Directors of the Company at the meeting held today i.e. 1st August, 2025 has approved, subject to necessary approvals, the Scheme of Amalgamation of Sresta Natural Bioproducts Private Limited and Wimco Limited, wholly owned subsidiaries, with the Company under Sections 230 and 232 of the Companies Act, 2013. Pending approval, no effect of the same has been given in these results.
7. Discontinued Operations represents operations of the Hotels Business of the Company (excluding ITC Grand Central, Mumbai) which was demerged pursuant to the Scheme of Arrangement amongst the Company and ITC Hotels Limited and their respective shareholders and creditors under Sections 230 to 232 read with the other applicable provisions of the Companies Act, 2013 (‘the Scheme’) w.e.f. 1st January, 2025, being the Appointed Date and the Effective Date of the Scheme. Comparative information has been presented accordingly.
Brief particulars of the Discontinued Operations are given as under (Rs. in Crores):